Participants
±
LYMPHOMA, MULTIPLE MYELOMA (MM)
The flow chart of study selection was presented in detail in Flowchart of the randomized controlled trial. The chart depicts the subjects screened before the study, those recruited for Vaccination, and the processes for selecting or excluding patients.
Baseline characteristics of participants based on the homologous and heterologous prime-boost COVID-19 vaccination in autologous hematopoietic stem cell transplant (auto-HSCT) recipients.Data are presented as frequency (%), mean (± standard deviation) and median (Q1- Q3)RBD-TT-Conjugated, Receptor-Binding Domain (RBD)-Tetanus Toxoid (TT); ISR, Immune Status RatioHSCT, Hematopoietic Stem Cell Transplantation; MM, Multiple MyelomaThe indications for auto-HSCT in the RBD-TT conjugated and inactivated booster groups were multiple myeloma (MM) (53%, 61%) and lymphoma (47%, 39%). Before auto-HSCT, 83% of patients in the RBD-TT conjugated arm and 90% in the inactivated arm were completely immunized against SARS-CoV-2. Seventeen (57%) of the homologous arm and 19 (61%) of the heterologous arm had a history of PCR-positive COVID-19 before auto-HSCT. Nevertheless, there were no statistically significant differences between the two randomized groups’ baseline characteristics.